Cobalt Oxide Nanoparticles

Cobalt Oxide Nanoparticles as an Alternative Vaccine Adjuvant

Co3O4NP stimulate Th1-type immune responses in vivo and could be useful as a vaccine adjuvant where both Th1 and Th2 responses are needed

About

Edinburgh researchers have shown that cobalt oxide nanoparticles (Co3O4NP) were capable of inducing a Th1 response without a severe delayed-type hypersensitivity pathology in lungs in vivo. Using the model antigen OVA, anti-OVA responses induced by Co3O4NP were compared to a commercially available aluminium containing adjuvant. Toxicity was also assessed at the injection site and cytotoxicity for antigen presenting cells was evaluated using a mouse macrophage cell line. Co3O4NP was observed to induce a balanced Th1 and Th2 response to the model antigen with little evidence of allergy, inflammation or toxicity at injection sites (s.c. and i.p.) Further Details: Adjuvanticity and toxicity of cobalt oxide nanoparticles as an alternative vaccine adjuvant. Cho WS et al, Nanomedicine 2012, 7(10) NiO and Co3O4 nanoparticles induce lung DTH-like responses and alveolar lipoproteinosis. Cho WS et al, Eur. Respir. J. 2012, 39: 546

Key Benefits

1. Potential to enhance immune response to vaccines against intracellular pathogens 2. Use as an adjuvant where both Th1 and Th2 responses are needed to clear pathogens

Applications

1. Potential to enhance immune response to vaccines against intracellular pathogens 2. Use as an adjuvant where both Th1 and Th2 responses are needed to clear pathogens

Register to view this innovation

  • Access all of the innovation information
  • Contact the innovator
  • Follow this innovation's progress
  • View innovation updates